The coronavirus outbreak in China seemed to be getting under control after a steady decline in new cases. Then, Thursday morning in China, authorities in Hubei province announced almost 15,000 new ones. Most of them appear to from be a backlog of thousands of negative diagnoses from less-than-reliable tests. But they're confirmation that outside experts who have been modeling the outbreak are right: The disease, now named Covid-19, has spread far deeper in the province than official numbers reflected. (Bloomberg is tracking developments in the outbreak here.) They also herald a frightening risk of collateral damage. Under the new criteria, anyone with the virus's flu-like symptoms plus a chest scan that shows signs of pneumonia in the lung is treated as a positive. It will result in more people being diagnosed and sent to treatment and isolation centers. It's almost certain to act as a crude dragnet that catches up people who have other respiratory diseases—like the flu—but not the new coronavirus. Those people will go into the province's machinery of containment, putting some of the uninfected into far closer contact with people who actually do have the virus. If they don't have the coronavirus when they're caught up in the newly broadened system of diagnosis and quarantine, they're more likely to get it.—Drew Armstrong  Medical staff receive a patient infected with the novel coronavirus at the temporary hospital in Wuhan, China. Photographer: Xiao Yijiu/Xinhua via Getty Images Here's what else we're watching:The Bernie rally. Health-insurance stocks surged after Bernie Sanders won the New Hampshire Democratic primary. Why? Investors think Trump can beat the self-described socialist in the presidential election. Pricing plans. While the Democrats battle to take him on November, Trump is looking for ways to bring down prescription prices to protect himself from attacks on his health-care record. Capital injections. Moderna said this week it was selling $500 million in stock, becoming the latest and biggest company to go to Wall Street to get more money to fund research into coronavirus vaccines. Changes at CVS. The health conglomerate put a company veteran in charge of its Caremark business, after the exit of former Eli Lilly executive Derica Rice, who'd joined in 2018. The move follows a board shakeup. Listen up. On the latest season on the Prognosis podcast, we tell how the $4 trillion American health-care system became so expensive and inefficient, and what some people are trying to do about it. Download it here on Apple devices, and here on Android.  Got this newsletter forwarded to you? Sign up to get it every Thursday by clicking here.
We want to hear from you. If you have feedback, questions or potential story ideas, reach out to me at darmstrong17@bloomberg.net | 
Post a Comment